These statistically robust efficacy outcomes, combined with manageable safety profiles (Grades 3 and 4 TRAE 30.1% vs. 52.5%), culminated in the FDA's May 18, 2020 label update (BLA 761034 s15), establishing atezolizumab as the standard first‐line therapy for metastatic NSCLC patients exhibiting PD‐L1‐high expression (TC ≥ 50% or IC ≥ 10%) [26]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.